Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$6.46
+0.10 (+1.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $437.0M · quality 82.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
58/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
14.0x
↓EV/EBITDA
7.2x
↓ROE
11.1%
↑Gross Margin
52.5%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.2%
FCF CAGR
+9.6%
FCF margin
23.4%
FCF / Net income
1.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.24B · net income $320.0M · FCF $524.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.24B | $2.24B | $2.69B | $2.91B | $2.72B |
| Net Income | $320.0M | $320.0M | $242.7M | $199.6M | $104.7M |
| EBITDA | $513.3M | $513.3M | $438.0M | $390.5M | $308.2M |
| EPS | 0.46 | 0.46 | 0.34 | 0.26 | 0.14 |
| Gross Margin | 52.5% | 52.5% | 51.7% | 57.9% | 55.9% |
| Operating Margin | 15.6% | 15.6% | 12.6% | 11.2% | 7.9% |
| Net Margin | 14.3% | 14.3% | 9.0% | 6.9% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.07 | 0.15 |
| Current Ratio | 3.92 | 3.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $524.9M | $524.9M | $437.0M | $397.7M | $398.2M |
| Returns | |||||
| ROE | 11.1% | 11.1% | 8.4% | 6.7% | 3.5% |
| Valuation | |||||
| P/E | 14.04 | 14.04 | 17.50 | 26.46 | 42.71 |
| EV/EBITDA | 7.18 | 7.18 | 8.68 | 12.52 | 13.77 |
| P/B | 1.55 | 1.55 | 1.48 | 1.78 | 1.51 |
| Growth & Yield | |||||
| Revenue Growth | -16.6% | -16.6% | -7.7% | 7.1% | — |
| EPS Growth | 35.3% | 35.3% | 30.8% | 85.7% | — |
| Dividend Yield | 7.7% | 7.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
7.6%
EPS terminal req.
$0.57
Spread vs growth
27.7%
5Y implied EPS CAGR
8.6%
EPS terminal req.
$0.69
Spread vs growth
26.7%
10Y implied EPS CAGR
9.3%
EPS terminal req.
$1.12
Spread vs growth
26.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.9%
Start / end P/E
18.2x → 14.0x
EPS bridge
0.34 → 0.46
Residual
-8.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.